Seattle Genetics shares fall on lymphoma trial suspension
This article was originally published in Scrip
Executive Summary
Seattle Genetics' shares have dropped on news that it has abandoned the Phase IIb clinical trial of dacetuzumab (SGN-40), for the treatment of diffuse large B-cell lymphoma.